[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.119.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 1986

Serotonin Function in Panic DisordersThe Effect of Intravenous Tryptophan in Healthy Subjects and Patients With Panic Disorder Before and During Alprazolam Treatment

Author Affiliations

From the Clinical Neuroscience Research Unit, Ribicoff Research Facilities, Connecticut Mental Health Center, and the Department of Psychiatry, Yale University School of Medicine, New Haven.

Arch Gen Psychiatry. 1986;43(11):1059-1065. doi:10.1001/archpsyc.1986.01800110045006
Abstract

• Preclinical evidence suggests that alterations in serotonin function may relate to the development of anxiety and the therapeutic effectiveness of antianxiety treatments. Serotonin increases prolactin release, and intravenous administration of the serotonin precursor, tryptophan, produces reliable elevations in serum prolactin levels. To evaluate serotonergic function, the effects of intravenous tryptophan on prolactin secretion were determined in 23 drug-free patients meeting DSM-III criteria for agoraphobia with panic attacks ór panic disorder and 21 age- and sex-matched healthy subjects. In nine of the patients the tryptophan infusion was repeated during long-term alprazolam treatment. The ability of tryptophan to increase prolactin levels was not different between the patients and healthy subjects and was not altered by alprazolam treatment. These findings suggest serotonin function may be normal in panic anxiety disorders and the antipanic mechanism of action of alprazolam may be unrelated to effects on serotonin activity.

×